A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancer

摘要: Background Gemcitabine plus cisplatin (GC) and vinorelbine (VC) are active well-tolerated regimens for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). We conducted this study to compare safety efficacy these as front-line chemotherapy NSCLC. Methods Eligible were randomized receive either gemcitabine (1000 mg/m2) on days 1, 8, 15 (80 day (arm GC), or (20 VC). Treatments repeated every 28 days. The costs retrieved from Health Care Reporting System Chang Gung Memorial Hospital at time final data analysis. Results Eighty-three (GC, n=39; VC, n=44) enrolled in study. Seventy-three analyzed. Response rates 38% 31% median survivals 12.9 9.0 months 34 GC arm 39 VC arm, respectively. One-year survival was 55.9% 33.3% arm. There no difference response rate (p=0.622), progression free (p=0.443) (p = 0.4197) between two arms. Grade 3-4 toxicities vomiting (GC: 16.3% vs. VC: 36.3%), neutropenia 14.7% 20%), thrombocytopenia 8.68% 5%). a significant increase all-grade (p=0.002) had higher total expenses than (p=0.020). Conclusions Both yielded similar efficacies